Latest Radium Stories
Invado Pharmaceuticals announced the acceptance of a NeutraSal antimicrobial pilot study poster at American Radium Society 95th Annual Meeting held in Scottsdale, AZ. In the study results, NeutraSal demonstrated antimicrobial properties that may benefit cancer patients. Pomona, NY (PRWEB) May 07, 2013 Invado Pharmaceuticals announced the acceptance of a NeutraSal antimicrobial pilot study poster at American Radium Society 95th Annual Meeting held in Scottsdale, AZ. In the study results,...
WAYNE, N.J., Feb. 13, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "We are pleased the FDA has granted priority review...
WAYNE, N.J., Dec. 14, 2012 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "If approved, radium-223 has the potential to play a key role in the treatment of men with CRPC that has metastasized to...
WAYNE, N.J., June 4, 2012 /PRNewswire/ -- Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride[*] in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.[1] Radium-223 dichloride significantly increased overall survival (HR=0.695, p=0.00007).((1) )The median overall survival (OS) benefit in patients given radium-223...
WAYNE, N.J., May 16, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on Nexavar® (sorafenib) tablets and several of its investigational oncology compounds will be presented in a scientific forum at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago, IL. These data, including oral presentations of two Late-Breaking Abstracts on the late-stage compounds regorafenib and radium-223 chloride, reflect Bayer's commitment to...
Plants have long been known as the lungs of the earth, but a new finding has found they may also play a role in electrifying the atmosphere. Scientists have long-suspected an association between trees and electricity but researchers from Queensland University of Technology (QUT) think they may have finally discovered the link. Dr Rohan Jayaratne and Dr Xuan Ling from QUT's International Laboratory for Air Quality and Health (ILAQH), led by Professor Lidia Morawska, ran experiments in...
WAYNE, N.J., Feb. 2, 2012 /PRNewswire/ -- Bayer HealthCare, LLC today announced that the U.S. Food and Drug Administration agreed that Bayer can proceed with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC)/hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases. Radium-223 chloride will be made available to patients through qualified clinical sites...
NORRISTOWN, Pa., Feb. 1, 2012 /PRNewswire-USNewswire/ -- The Department of Environmental Protection is asking anyone who knows the history of an antique medical kit found in a Chester County trash bin to contact the agency's Bureau of Radiation Protection. "The radioactive material may have been contained in the kit for more than 80 years," Bureau Director David Allard said. "The metal box likely came from a basement, an attic or a collector's stash. Anyone who tampered with it or...
WAYNE, N.J., Sept. 23, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals today announced that the investigational drug radium-223 chloride showed positive data in the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial. The study met its primary endpoint by significantly improving overall survival by 44% (p=0.00185, HR=0.695) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. All of the main secondary efficacy endpoints...
WAYNE, N.J., Sept. 13, 2011 /PRNewswire/ -- Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden. These presentations, including the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) data evaluating radium-223 chloride in patients with castration-resistant prostate cancer (CRPC), will highlight the...
Latest Radium Reference Libraries
Actinium is a radioactive chemical element. The symbol for Actinium is Ac and the atomic number is 89. Actinium was discovered in 1899 by French chemist André-Louis Debierne. It was the first non-primordial radioactive element to be isolated. Actinium is amongst a group of 15 similar elements within the periodic table that make up the actinoid series. This substance was also independently discovered by Friedrich Oskar Giesel in 1902 and named it emanium in 1904. In 1904 he named it...
